Venlafaxine Pharmacogenetics: a Comprehensive Review

Suwała, Justyna; Machowska, Marta; Wiela-Hojeńska, Anna

doi:10.2217/pgs-2019-0031

Cited by 29 publications

(23 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Serotonin–norepinephrine reuptake inhibitors (SNRIs) that are potent inhibitors of both SERT and NET, such as duloxetine [ 19 ] and venlafaxine [ 20 ], were approved as antidepressants or anxiolytics in clinical practice. Triple reuptake inhibitors (TRIs) concomitantly inhibit SERT, DAT, and NET.…”

Section: Introductionmentioning

confidence: 99%

Two Lignan Glycosides from Albizia julibrissin Durazz. Noncompetitively Inhibit Serotonin Transporter

Huang

Liu

et al. 2022

Pharmaceuticals

View full text Add to dashboard Cite

Albizia julibrissin Durazz. is one of the most common herbs used for depression and anxiety treatment, but its molecular basis and mechanism of action as an antidepressant or anxiolytic drug are not understood. In this study, we separated and identified two lignan glycosides that inhibit serotonin transporter (SERT) noncompetitively by decreasing Vmax with little change in Km for its fluorescence substrate. In addition, treatment with lignan glycosides did not alter total and cell surface expression levels of the transporter protein. The two compounds decreased the accessibility of a cysteine residue placed in the extracellular substrate permeation pathway by inducing a conformational shift toward an outward-closed state of SERT. These results are consistent with molecular docking for the association of the lignan glycosides to the allosteric site in SERT. The present work supports the proposal that these compounds act on SERT by a novel underlying mechanism of action different from that of conventional antidepressant drugs.

show abstract

Section: Introductionmentioning

confidence: 99%

Two Lignan Glycosides from Albizia julibrissin Durazz. Noncompetitively Inhibit Serotonin Transporter

Huang

Liu

et al. 2022

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…Cinnarizine and verapamil may be used as alternative drugs to prevent migraines, e.g., in refractory migraine cases or when flunarizine is not available ( Knezevic et al, 2018 ). Food and Drug Administration (FDA) (2019) and European Medicines Agency (2018) have recently approved using CGRP monoclonal antibodies (erenumab, galcanezumab, fremanezumab, and eptinezumab) for the prevention treatment of chronic migraine ( Steiner et al, 2019 ; Moreno-Ajona et al, 2020 ; Sacco et al, 2019 ; Suwała et al, 2019 ; Shams et al, 2006 ). Therapy with botulinum toxin type A (onabotulinumtoxinA) is recommended by EHF and AAN as an equally significant and effective alternative for migraine prevention ( Digre, 2019 ; Affatato et al, 2021 ; Herd et al, 2018 ) ( Table 2 ).…”

Section: Important Drug Groups Used For the Treatment Of Headache Dis...mentioning

confidence: 99%

“…Venlafaxine has been to a lesser extent investigated in pharmacogenetic studies than, for example, selective serotonin reuptake inhibitors, and the results of already performed investigations are, in some parts, contradictory or originate from single studies. However, it seems that several genetic polymorphisms are involved in its effectiveness and safety ( Suwała et al, 2019 ). People with CYP2D6 *6/*4, *5/*4 , or *6/*6 (PMs) are more likely to experience gastrointestinal adverse effects such as nausea, vomiting, and diarrhea ( Shams et al, 2006 ).…”

Section: Pharmacogenetics Of Important Drugs Used In Migraine Tension...mentioning

confidence: 99%

Pharmacogenetics in Primary Headache Disorders

et al. 2022

View full text Add to dashboard Cite

Primary headache disorders, such as migraine, tension-type headache (TTH), and cluster headache, belong to the most common neurological disorders affecting a high percentage of people worldwide. Headache induces a high burden for the affected individuals on the personal level, with a strong impact on life quality, daily life management, and causes immense costs for the healthcare systems. Although a relatively broad spectrum of different pharmacological classes for the treatment of headache disorders are available, treatment effectiveness is often limited by high variances in therapy responses. Genetic variants can influence the individual treatment success by influencing pharmacokinetics or pharmacodynamics of the therapeutic as investigated in the research field of pharmacogenetics. This review summarizes the current knowledge on important primary headache disorders, including migraine, TTH, and cluster headache. We also summarize current acute and preventive treatment options for the three headache disorders based on drug classes and compounds taking important therapy guidelines into consideration. Importantly, the work summarizes and discusses the role of genetic polymorphisms regarding their impact on metabolism safety and the effect of therapeutics that are used to treat migraine, cluster headache, and TTH exploring drug classes such as nonsteroidal anti-inflammatory drugs, triptans, antidepressants, anticonvulsants, calcium channel blockers, drugs with effect on the renin–angiotensin system, and novel headache therapeutics such as ditans, anti-calcitonin-gene-related peptide antibodies, and gepants. Genetic variants in important phase I-, II-, and III-associated genes such as cytochrome P450 genes, UGT genes, and different transporter genes are scrutinized as well as variants in genes important for pharmacodynamics and several functions outside the pharmacokinetic and pharmacodynamic spectrum. Finally, the article evaluates the potential and limitations of pharmacogenetic approaches for individual therapy adjustments in headache disorders.

show abstract

“…Venlafaxine (brand name Effexor) is an antidepressant that is used to treat the depression, anxiety, and panic disorder [54,55]. Both venlafaxine and its major metabolite, desvenlafaxine, belong to the drug class of SNRIs.…”

Section: Venlafaxinementioning

confidence: 99%

Pharmacogenomic Biomarkers and Their Applications in Psychiatry

Kam

Jeong

2020

Genes

View full text Add to dashboard Cite

Realizing the promise of precision medicine in psychiatry is a laudable and beneficial endeavor, since it should markedly reduce morbidity and mortality and, in effect, alleviate the economic and social burden of psychiatric disorders. This review aims to summarize important issues on pharmacogenomics in psychiatry that have laid the foundation towards personalized pharmacotherapy and, in a broader sense, precision medicine. We present major pharmacogenomic biomarkers and their applications in a variety of psychiatric disorders, such as depression, attention-deficit/hyperactivity disorder (ADHD), narcolepsy, schizophrenia, and bipolar disorder. In addition, we extend the scope into epilepsy, since antiepileptic drugs are widely used to treat psychiatric disorders, although epilepsy is conventionally considered to be a neurological disorder.

show abstract

Venlafaxine Pharmacogenetics: a Comprehensive Review

Cited by 29 publications

References 67 publications

Two Lignan Glycosides from Albizia julibrissin Durazz. Noncompetitively Inhibit Serotonin Transporter

Two Lignan Glycosides from Albizia julibrissin Durazz. Noncompetitively Inhibit Serotonin Transporter

Pharmacogenetics in Primary Headache Disorders

Pharmacogenomic Biomarkers and Their Applications in Psychiatry

Contact Info

Product

Resources

About